Company: MDCXW
Filing Date: 2025-08-12
Form Type: 424B3
Source: 0001062993-25-014091
Chunk: 15

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 424B3
Chunk 15
---
 of June 30, 2025, there have been no sales made under the SEPA.

6. Stock-based compensation At June 30, 2025, the Company had in place a stock option plan for employee, non-employee directors, and consultants of the Company (the "Plan"). The Plan provides both for the direct award or sale of shares and for the grant of options to purchase shares. Under the plan the total number of shares available for options cannot exceed 10% of the Company's issued and outstanding common shares at the time of any grant. The Company is authorized to issue options to employees, non-employee directors and consultants under the plan. 13

On June 25, 2024, the Board of Directors of the Company approved the acceleration of vesting for all outstanding share options to June 25, 2024, resulting in the Company recognizing the remaining expense for all share options outstanding and unvested as of that date. The following table summarizes option transactions for the Plan:

|                                  |     | Number of 
   options |     |       Weighted 
        average 
 exercise price 
              $ |     |         Weighted 
          average 
        remaining 
 contractual life 
          (years) |     |       Aggregate 
 intrinsic value 
               $ |
| Outstanding at December 31, 2024 |     | 1,185,000 |     |           1.47 |     |             4.18 |     |            1.18 |
| Granted                          |     |   100,000 |     |           2.60 |     |             5.00 |     |               - |
| Outstanding at June 30, 2025     |     | 1,285,000 |     |           1.56 |     |             3.79 |     |            1.43 |
| Exercisable at June 30, 2025     |     |   980,000 |     |           1.25 |     |             4.01 |     |            1.74 |
| Unvested at June 30, 2025        |     |   305,000 |     |           2.56 |     |             4.44 |     |               - |

As of June 30, 2025, there were $541,867 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average